United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,166.50. The transaction was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Stock Up 1.5 %

United Therapeutics stock opened at $235.31 on Thursday. The company’s 50 day simple moving average is $230.70 and its 200 day simple moving average is $228.38. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The firm has a market capitalization of $11.07 billion, a price-to-earnings ratio of 11.86 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same quarter last year, the firm earned $2.67 EPS. United Therapeutics’s quarterly revenue was up 25.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 23.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rise Advisors LLC bought a new position in United Therapeutics in the first quarter valued at approximately $32,000. Atlas Capital Advisors LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $51,000. Northwestern Mutual Wealth Management Co. lifted its stake in United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 65 shares in the last quarter. GAMMA Investing LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $43,000. Finally, Neo Ivy Capital Management bought a new position in United Therapeutics in the second quarter valued at approximately $48,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. HC Wainwright reiterated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $292.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.